Inventory (Notes)

12 Months Ended

Dec. 31, 2017

Inventory Disclosure [Abstract]

Inventory

Inventory

Inventory consists of the following at December 31, 2017 (in thousands):

	December 31, 2017		December 31, 2016
Raw materials	$	3,852	$	—
Work in process	313		—
Finished goods	201		—
Total inventories	$	4,366	$	—

Inventory acquired prior to receipt of the marketing approval for TYMLOS, totaling approximately $1.6 million, was expensed as research and development expense as incurred. The Company began to capitalize the costs associated with the production of TYMLOS upon receipt of FDA approval on April 28, 2017.

Finished goods manufactured by the Company have a 30-month shelf life from date of manufacture.